

Product Information Sheet for NR-15447

SUPPORTING INFECTIOUS DISEASE RESEARCH

A/H9N2 Influenza Vaccine Surface Antigen Inactivated, with MF59C.1 Adjuvant (A/CK/HK/G9/1997), 3.75 Micrograms HA

Catalog No. NR-15447

This reagent is the property of the U.S. Government.

For research use only. Not for human use.

Contributor:

National Institutes of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)

Manufacturer:

Chiron Corporation (Novartis International AG)

Product Description:

NR-15447 is a formalin-inactivated surface antigen vaccine prepared from an egg-grown high-growth influenza virus reassortant containing the hemagglutinin (HA) and neuraminidase antigens from the Y280-like A/chicken/Hong Kong/G9/1997 strain and the internal genes from A/Puerto Rico/8/1934. NR-15447 is formulated with MF59C.1 adjuvant.

Please note that this vaccine preparation is being released <u>for research use only</u> and not for human use.

Material Provided:

Each syringe contains 3.75 μg (0.5 mL suspension) of the hemagglutinin (HA) antigen from influenza virus A/chicken/Hong Kong/G9/1997 (H9N2) and MF59C.1 adjuvant.

Packaging/Storage:

NR-15447 is packaged in a pre-filled syringe. The product is provided on refrigerated bricks and should be stored at 2°C to 8°C immediately upon arrival. Do not freeze. Protect from light. Shake before use.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: A/H9N2 Influenza Vaccine Surface Antigen Inactivated, with MF59C.1 Adjuvant (A/CK/HK/G9/1997), 3.75 Micrograms HA, NR-15447."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. <u>Biosafety in Microbiological and Biomedical Laboratories</u>. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

- Atmar, R. L., et al. "Safety and Immunogenicity of Nonadjuvanted and MF59-Adjuvanted Influenza A/H9N2 Vaccine Preparations." <u>Clin. Infect. Dis.</u> 43 (2006): 1135-1142. PubMed: 17029131.
- Chen, H., et al. "Generation and Evaluation of a High-Growth Reassortant H9N2 Influenza A Virus as a Pandemic Vaccine Candidate." <u>Vaccine</u> 21 (2003): 1974-1979. PubMed: 12706686.

ATCC[®] is a trademark of the American Type Culture Collection.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org
Tel: 800-359-7370

Fax: 703-365-2898